nature research

Corresponding author(s): Jian Wang, Qianbing Wan

Last updated by author(s): Jan 18, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

Fora	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
	X	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.	
×		A description of all covariates tested	
×		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>	
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
x		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated	
·		Our web collection on statistics for biologists contains articles on many of the points above.	

Software and code

Policy information about <u>availability of computer code</u>				
Data collection	Data were collected with various laboratory instruments and equipment. Such as: Laser confocal microscopy (Nikon N-SIM, Japan), Liquid chromatography-mass spectrometry (LC-MS, Thermo Fisher Scientific, USA), Reverse phase high performance liquid chromatography (HPLC, Shimadzu LC-20AD, Japan), inverted fluorescence microscopy (Leica, Germany), etc.			

Data analysis Origin 9.1, Graph Pad Prism 9, Image J, IBM SPSS Statistics v22.0, Microsoft Excel 16.44.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that all the relevant data supporting the findings of this study are available within the article and its Supplementary Information files and Supplementary Movies. The source data underlying Figs. 2a, c-h; 3a-e; 4c-e; 5c, d, g; 6e, f; 7c-n; 8a, C and Supplementary Figs. 1a, g-i; 3a, b; 4d-g; 5a-c; 7a, b; 8a-b; 10 are provided as a Source Data file. Source data are provided with this paper.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

× Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes were chosen based on previously published literature and protocols in the field with a similar setup that showed statistical significance. For each experiment, we have adopted at least n=3 biological replicates to calculate the statistical value of each analysis and the exact sample sizes and statistical data for each experiment are reported in the figure legends.
Data exclusions	No data were excluded from the analyses.
Replication	All experiments were repeated at least three times with reproducibility. All attempts at replication were successful and the exact numbers are indicated in the figure legends or table for all experiments.
Randomization	Rats were assorted randomly to cages when received from the vendor.
Blinding	The investigators were blinded to group allocation during data collection and analysis.

Reporting for specific materials, systems and methods

Methods

X

×

n/a Involved in the study

ChIP-seq

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

MRI-based neuroimaging

Materials & experimental systems

n/a	Involved in the study
	X Antibodies
	Eukaryotic cell lines
×	Palaeontology and archaeology
	× Animals and other organisms
×	Human research participants
×	Clinical data
×	Dual use research of concern

Antibodies

Antibodies used	Anti-cytokeratin 5 rabbit monoclonal antibody (CK5, Abcam, Cat no. ab52635, Lot. GR3292032-7, dilution: 1:100), anti-cytokeratin13 rabbit polyclonal antibody (CK13, Servicebio, Cat no. GB11802, dilution: 1:500), and CD11b polyclonal antibody (CD 11b, Bioss, Cat no. bs-1014R, Lot. AG05216987, dilution: 1:100).
Validation	All antibodies used in experiments are commercially available and have been validated by the manufacturer. All validation statements can be found on the respective antibody website:
	Anti-cytokeratin 5 rabbit monoclonal antibody https://www.abcam.cn/cytokeratin-5-antibody-ep1601y-cytoskeleton-marker-ab52635.html
	Anti-cytokeratin13 rabbit polyclonal antibody https://www.servicebio.cn/goodsdetail?id=496
	CD11b polyclonal antibody https://www.biossusa.com/products/bs-1014r

Eukaryotic cell lines

Policy information about <u>cell lines</u>					
Cell line source(s)	HGECs, HOK and TR146 cell lines were purchased from GuangZhou Jennio Biotech Co., Ltd. (China).				
Authentication	Authentication was performed by analysis of morphology.				
Mycoplasma contamination	All cell lines tested negative for mycoplasma contamination.				

No commonly misidentified lines were used in this study.

Animals and other organisms

Policy information about	studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals	Eight-week-old male Sprague-Dawley rats (250 ± 10 g) were obtained from Chengdu Dashuo Bio-Technology Co., Ltd. (China) in this study.
Wild animals	This study did not involve use of wild animals.
Field-collected samples	This study did not involve use of field-collected samples.
Ethics oversight	All experiments involving animals were carried out in compliance with the Institutional Animal Care and Use Committee of Sichuan University, Chengdu, China.

Note that full information on the approval of the study protocol must also be provided in the manuscript.